Elsevier

Clinical Therapeutics

Volume 19, Issue 6, November–December 1997, Pages 1294-1308
Clinical Therapeutics

Review Article
Topiramate: a review of preclinical, pharmacokinetic, and clinical data

https://doi.org/10.1016/S0149-2918(97)80006-9Get rights and content

Abstract

The antiepileptic drug (AED) topiramate is a monosaccharide derivative with a sulfamate functionality. It modulates voltage-dependent sodium conductance, potentiates gamma-aminobutyric acid—evoked currents, and blocks the kainate/AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) subtype of the glutamate receptor. Topiramate is rapidly absorbed and has linear, proportional, steady-state pharmacokinetics. It has no known clinically significant effect on plasma levels of carbamazepine, valproic acid, or phenobarbital, although it may increase plasma concentrations of phenytoin in some patients. When topiramate is used with hepatic enzyme-inducing AEDs, its plasma concentrations are approximately 50% lower than when it is administered alone. The efficacy of topiramate 200 to 1000 mg/d administered in two divided doses as adjunctive therapy for partial-onset seizures was investigated in five double-masked, placebo-controlled trials. The median percentage reduction in average monthly seizure frequency from baseline was 12% for placebo, compared with 30% for the 200-mg/d group and 48% for the 400-mg/d group. At a dosage of 400 mg/d, a seizure reduction of 75% or greater was seen in 22% of topiramate patients, compared with 7% of those receiving placebo; up to 9% of topiramate patients, compared with none of those receiving placebo, became seizure free. Although little additional efficacy was seen at dosages of 600, 800, and 1000 mg/d, dosing should be individualized, because some patients may respond to higher dosages. When topiramate is combined with other AEDs, the most common side effects at dosages of 200 to 400 mg/d are somnolence, dizziness, ataxia, psychomotor slowing, hesitant speech, and wordfinding difficulties. Most patients who experienced adverse events during the first 8 weeks of the trials no longer experienced them by their last visit. Although there was a 1.5% incidence of renal stones that may be associated with carbonic anhydrase inhibition, more than 75% of patients experiencing a stone continued on therapy.

References (35)

  • M Sharief et al.

    Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy

    Epilepsy Res

    (1996)
  • MA Rogawski et al.

    Antiepileptic drugs: Pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds

    Pharmacol Rev

    (1990)
  • BE Maryanoff et al.

    Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate and related compounds

    J Med Chem

    (1987)
  • PN Patsalos et al.

    Newer antiepileptic drugs: Towards an improved risk-benefit ratio

    Drug Saf

    (1994)
  • SD Brown et al.

    The novel anticonvulsant topiramate enhances GABA-mediated chloride flux

    Epilepsia

    (1993)
  • HS White et al.

    The investigational anticonvulsant topiramate potentiates GABA-evoked currents in mouse cortical neurons

    Epilepsia

    (1995)
  • S Sombati et al.

    Effects of topiramate on sustained repetitive firing and low Mg2+-induced seizure discharges in cultured hippocampal neurons

    Epilepsia

    (1995)
  • L Severt et al.

    Topiramate selectively blocks kainate currents in cultured hippocampal neurons

    Epilepsia

    (1995)
  • RP Shank et al.

    Topiramate: Preclinical evaluation of a structurally novel anticonvulsant

    Epilepsia

    (1994)
  • CL Harden

    New antiepileptic drugs

    Neurology

    (1994)
  • Data on file, Robert Wood Johnson Pharmaceutical Research...
  • DE Easterling et al.

    Plasma pharmacokinetics in topiramate, a new anticonvulsant, in humans

    Epilepsia

    (1988)
  • DR Doose et al.

    Multiple-dose pharmacokinetics of topiramate in healthy male subjects

    Epilepsia

    (1988)
  • M Bialer

    Comparative pharmacokinetics of the newer antiepileptic drugs

    Clin Pharmacokinet

    (1993)
  • DR Doose et al.

    The effect of food on the bioavailability of topiramate from 100-mg and 400-mg tablets in healthy male volunteers

    Epilepsia

    (1992)
  • LG Gisclon et al.

    The pharmacokinetics (PK) of topiramate (T) in subjects with renal impairment (RI) as compared to matched subjects with normal renal function (NRF)

    Pharm Res

    (1993)
  • LG Gisclon et al.

    The pharmacokinetics (PK) of topiramate (T) in subjects with end-stage renal disease undergoing hemodialysis

    Clin Pharmacol Ther

    (1994)
  • Cited by (0)

    View full text